Ekaterina Smirnyagina
Senior Partner and Head of Life Sciences @ Oxford Science Enterprises
Oxford, United Kingdom
Ekaterina Smirnyagina is a Series A investor at Oxford Science Enterprises in Oxford focused on Health Care and Therapeutics. Ekaterina Smirnyagina is based out of Oxford, Oxfordshire, and is the senior partner and head of life sciences of Oxford Science Enterprises. Ekaterina previously worked at MiroBio as a board member. Ekaterina Smirnyagina attended the University of Wisconsin-Madison.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 17%
Last updated:
For AI agents: llms.txt
Industries Ekaterina Smirnyagina invests in
Stages Ekaterina Smirnyagina invests in
Countries Ekaterina Smirnyagina invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 2 (33%)
- Therapeutics 1 (17%)
- Manufacturing 1 (17%)
- Medical Device 1 (17%)
Stage
- Series A 2 (33%)
- Series B 2 (33%)
- Series C 2 (33%)
Country
- Belgium 1 (17%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Beacon Therapeutics
|
Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $170M / Series B / Jun 03, 2024 | |
|
Beacon Therapeutics
|
Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $120.1M / Series A / Jun 12, 2023 | |
iSTAR Medical
|
iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium.By 2012, iSTAR received ISO 13485 and ISO 9001 Quality SystemsCertifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant. | $44.1M / Series C / Sep 05, 2019 | |
|
iSTAR Medical
|
iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium.By 2012, iSTAR received ISO 13485 and ISO 9001 Quality SystemsCertifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant. | $11.4M / Series B / Apr 12, 2016 | |
|
iSTAR Medical
|
iSTAR Medical SA was created in 2010 as a spinout of Healionics Corporation with support from Belgium's Region Wallonne government. In 2011, iSTAR expanded to its new eco-friendly R&D and Manufacturing facility in CREALYS Scientific Park near Namur, Belgium.By 2012, iSTAR received ISO 13485 and ISO 9001 Quality SystemsCertifications and achieved CE Mark approval of its first device - STARflo™ Glaucoma Implant. | $4.4M / Series A / Nov 21, 2013 | |
|
Beacon Therapeutics
|
Beacon Therapeutics is an ophthalmic gene therapy company that restores and improves vision and rare retinal diseases that result in blindness. | $75M / Series C |
Co-Investors
Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.
Oxford Science Enterprises Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alexis Dormandy
Chief Executive Officer
|
|||
|
Alexis Zervoglos
Senior Partner (Technology)
|
|||
Claire Brown
Partner ( Life Sciences)
|
|||
|
Ekaterina Smirnyagina
Senior Partner and Head of Life Sciences
|
|||
David Norwood
Chairman
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ekaterina Smirnyagina invest in?
Ekaterina Smirnyagina invests primarily in Health Care, Therapeutics and Manufacturing startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in Belgium. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ekaterina Smirnyagina?
Public channels for Ekaterina Smirnyagina include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ekaterina Smirnyagina last invest?
The most recent investment recorded for Ekaterina Smirnyagina closed in Jun 2024. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
